Nerve Repair And Regeneration Market (By Product: Biomaterial, Neurostimulation and Neuromodulation Devices [Deep Brain Stimulation Devices, Spinal Cord Stimulation Devices, Vagus Nerve Stimulation Devices, Sacral Nerve Stimulation Devices, Gastric Electric Stimulation Devices]; By Surgery: Stem Cell Therapy, Nerve Grafting, Direct Nerve Repair/Neurorrhaphy, Neurostimulation and Neuromodulation Surgeries) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026

Category : Healthcare and Pharmaceuticals | Delivery Format : PDF | Status: Published | Pages : 190


According to Acumen Research and Consulting, the global nerve repair and regeneration market size is expected to reach around US$ 17.2 bn by 2026 and will grow at a CAGR around 10.4 % throughout the forecast period 2019-2026.

The complicated, sensitive structures of the brain structure, backbone, and peripheral nerves are sensitive to various kinds of injury from neurodegenerative traumatism to Alzheimer's, Parkinson's, multiple system atrophy, and amyotrophic lateral sclerosis. Peripheral nerves, such as your muscles and your skin, connect your brain with your spinal cord to the others. These nerves are fragile and readily damaged, and thus the capacity of the brain to interact with muscles and organs can interfere. Including biomaterials and neurostimulation devices for nervous repair and regeneration goods.

The report provides analysis of global Nerve Repair And Regeneration market for the period 2015-2026, wherein 2019 to 2026 is the forecast period and 2018 is considered as the base year.

Market Dynamics

The main drivers of the market are rising neurological disorders and the powerful pipeline of significant businesses. Improved therapy effectiveness for neurological disorders is also probable to contribute to market growth owing to various technological developments. The Baxter marking for the marketing of' HEMOPATKH' the ready-to-use operational patch on the European market was finished by Baxter in March 2016. This patch is approved as a hemostatic system to avoid loss of blood or any other body fluid and to stop the shrinkage of dura mater during traumatic injuries to the brain, CNS or other body components.

In addition, a number of therapies are available to treat multiple Central Nerve System (CNS) illnesses, such as Parkinson's disease and Alzheimer's, as well as a wider range of apps. 326 million individuals had migraine pain and 24 million suffered from Alzheimer's disease in 2018, the World health organization reports says The World Health Organization (WHO).

Increased awareness, environmental influence, lifestyle, genetics, nutrition and physical injury can lead to these problems.

An annual meeting of the American Society for Hand Surgery (ASSH) reported in 2015 that the therapy of patients with high nerve endurance impairment may result in restoration of motive and sensory nerve functions by the processed nervous allogrfin. In 2015, a report was published. The regeneration of sensory nerve function and motor function was shown in 75 and 85 percent of patients receiving PNA allograft (Avance Nerve Graft, AxoGen).

Product Outlook

SCS was the biggest product segment in 2018, with a market share of over 40.0 per cent in 2018 and SCS was the biggest subdivision. The dominance of the segment has been driven by a large amount of commercially available backbone products and a broad variety of apps.

The market is likely to boost investment by important businesses in order to create more efficient equipment in the coming years. In May 2016, for example, the FDA approved the precision assembly system MRI Spinal Cord Stimulator System (Boston Scientific). The firm said that its system offers 70% more back pain relief.

Due to the development of technological advances, a broad range of applicaciones, public financing for innovation and biocompatibility, the segment biomaterials is expected to grow at the highest CAGR between 2019 and 2026. It is anticipated that superior products, namely biodegradable polymers, will improve spinal stabilisation, cure fractures and decrease hospitalization.

Surgery Outlook

Surgery divides the industry into immediate neurostimulation or neuromodulation, nerve grafting, stem cell treatment and operation of neurostimulation & neuromodulation. The biggest proportion of the market in 2018 was neurostimulation and neuromodulation surgery. Stamm cell therapy over the forecast years is anticipated to be the highest CAGR. Different public initiatives and approvals are expected to increase the market for clinical biomaterials. In the U.S., about 570 stem cell therapy clinics are offered and the number is anticipated to increase and therefore increase development in this segment.

The expected marketing of the products in future years is also expected to increase market growth owing to investments by businesses and study institutes. For example, the European Union awards CE mark approval for its scheme of sacred nerve modulation in June 2016 to Axonics Modulation Technologies. After a follow-up post-market clinical trial, the firm plans to commercialize it.

Based on the accessibility of several products and technological advancements in order to decrease chronic pain, the neurostimulation / neuromodulation surgery was the major part of the industry in 2018. For example, in April 2016, St. Jude launched the DRG-Dorsal Root Ganglion implant in the U.S. with an Axium Neurostimulator System. For complex regional pain syndrome I and II sufferers the scheme decreases chronic pain and could not be accomplished by traditional SCS.

Regional Stance

In 2018, North America became the market leader in the region as neural diseases and health support scenario expanded. Due to the existence of key market players, the availability of sophisticated technological devices is also a significant factor for the dominance of the region. In February 2016, for example, Medtronic plc introduced Reclaim DBS therapy to treat OBS (OBS). In addition, FDA approval was given in May 2016 by Boston Scientific's Precision Montage MRI-safe SCS, used for chronic pain.

Asia-Pacific is the region with the fastest growing population, improving patient consciousness, supporting public projects, lack of medical requirements and the emergence of innovative techniques. The region is growing fastest.

The main nations contributing to the development of the region are China, India, Japan, Australia and Singapore. In December 2015, a clinical trial of the treatment method test on the basis of human parthenetic stem cells (ISC-hpNSC), was approved for patients suffering with Parkinson's Disease by the Australian Therapeutics Good Administration (TGA). The approval is expected to drive the region's stem cell therapy market.

Market Segmentation

Global Nerve Repair And Regeneration Market, By Product

  • Biomaterial
  • Neurostimulation and Neuromodulation Devices
    • Deep Brain Stimulation Devices
    • Spinal Cord Stimulation Devices
    • Vagus Nerve Stimulation Devices
    • Sacral Nerve Stimulation Devices
    • Gastric Electric Stimulation Devices

Global Nerve Repair And Regeneration Market, By Surgery

  • Stem Cell Therapy
  • Nerve Grafting
  • Direct Nerve Repair/Neurorrhaphy
  • Neurostimulation and Neuromodulation Surgeries

Global Nerve Repair And Regeneration Market, By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa (MEA)

The market research study on “Nerve Repair And Regeneration Market - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026” offers detailed insights on global Nerve Repair And Regeneration market segments with market dynamics and their impact. The report also covers basic technology development policies.

Key Players & Strategies

The key corporations are AxoGen, Inc.; Boston Scientific, Inc.; Stryker Corporation; Baxter International, Inc.; St. Jude Medical, Inc.; Polyganics B.V. The contributors to the sector have a wide range of products for neurological disorders. In order to enhance therapy effectiveness, the market operators are in the process of implementing sophisticated products that in turn have greater market share. The Instance announced the results of the randomized controlled trial, WHISPER, at Boston Scientific Corporation in January 2018.

The WHISPER information shows that both SCS-based and sub-perception patients are delivering higher results. St Jude Medical introduced the DBS Lead and Infinity DBS system direction in June 2016 to promote movement-disorder therapies. It is intended so that Apple's mobile devices can be used by means of the Bluetooth connection as wireless controllers, and is the only upgradable DBS system for diseases such as tremor, dystonia and Parkinson's disease.

AxoGen developed its annual nerve repair platform in November 2017. The firm has added Breast Reconstruction and OSM to its portfolio, in relation to its already current portfolio for Upper Edges Trauma, Oral & Maxile Facial Procedures and Carpal & Cubital Tune Review.

Cart Summary